How does Zepbound work? GIP plus GLP-1
Zepbound gets described as another Ozempic with a new name, a once-weekly shot doing the same job under different branding. That description skips the one detail that actually matters. The active drug in Zepbound, tirzepatide, binds a second hormone receptor that Ozempic and Wegovy never touch, and the FDA's own label for the drug says so directly.
Semaglutide, the drug in Ozempic and Wegovy, copies one hormone, GLP-1, and works through that single receptor. Tirzepatide copies two hormones at once, which is why researchers in this field call it a dual agonist instead of grouping it with semaglutide. Our guide to how does ozempic work covers GLP-1 and semaglutide's single-receptor mechanism in full. This guide stays on what the second receptor adds and what it changes.
What follows covers what each receptor does on its own, how the two work together in the pancreas, gut, and brain, why one weekly injection keeps signaling for days, what the addition of obstructive sleep apnea to Zepbound's label actually showed, and where the well-known SURMOUNT-1 weight-loss numbers come from.
How does tirzepatide work?
Semaglutide, the drug in Ozempic and Wegovy, binds that single hormone, GLP-1, at one receptor. The Ozempic label describes semaglutide as about 94% identical in structure to the human version of that hormone. Tirzepatide, the drug in Zepbound and Mounjaro, occupies two receptors. The FDA's prescribing information for Zepbound names both directly: "tirzepatide is a GIP receptor and GLP-1 receptor agonist." That single sentence is the reason researchers call the drug class a dual agonist, and it is the detail that separates Zepbound from every semaglutide-based product sitting next to it on a comparison chart.
Zepbound's own label lists two separate approved uses. The first is "to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition," used alongside a reduced-calorie diet and increased physical activity. The second use, added to the label later, covers obstructive sleep apnea, which gets its own section below.
Both receptors trace back to the same kind of hormone. GIP and GLP-1 are both incretins, hormones your gut releases after you eat, timed to the meal rather than running constantly in the background. Semaglutide copies one of those signals. Tirzepatide copies both, and the second signal is where the rest of this guide picks up.
The second receptor: what GIP adds
GIP stands for glucose-dependent insulinotropic polypeptide. Researchers identified it as a gut hormone before GLP-1 drew similar attention, and for years it was studied mainly for its role in prompting the pancreas to release insulin after a meal, the glucose-dependent pattern GLP-1 also uses. Insulin only increases when blood sugar is actually elevated, which is one reason incretin-based drugs, with one receptor or two, carry a comparatively low risk of pushing blood sugar too low on their own.
Researchers started treating GIP and GLP-1 as partners instead of competing pathways. Tirzepatide engages both receptors from the same molecule, at the same time, rather than relying on GLP-1 alone and raising the dose. This distinction shapes how people describe the drug. Calling tirzepatide "a stronger GLP-1 drug" treats the GIP half as decoration. The FDA's mechanism-of-action language does not describe it that way. It names tirzepatide as an agonist at both receptors, with no hierarchy stated between them.
Researchers studying GIP receptor activity outside the pancreas have proposed that it also changes how fat tissue handles and stores lipids, a pathway separate from the appetite and digestion effects GLP-1 drives on its own. This extra pathway likely explains why combining the two receptors, instead of simply dosing semaglutide higher, produced different trial results than semaglutide alone. Those results are covered later in this guide.
How the two signals work together in your body
Picture both receptors acting at the same three stops: pancreas, stomach, and brain. In the pancreas, GIP and GLP-1 both push insulin release higher when blood sugar is elevated and both back off when it is not, the glucose-dependent pattern described above. The combined push appears to produce a larger glucose-lowering effect than either hormone alone, part of why tirzepatide carries its own separate diabetes indication, sold as Mounjaro, apart from Zepbound's weight-management and sleep apnea uses.
In the gut, GLP-1 does most of the work slowing gastric emptying, the mechanism behind food sitting in the stomach longer and fullness arriving sooner. Early nausea in tirzepatide users traces back to that same slower emptying, much like semaglutide, with a second pathway layered on top.
In the brain, GLP-1 receptors sit in the hypothalamus and hindbrain, regions that regulate hunger and fullness, and tirzepatide reaches them the way semaglutide does. Whether GIP receptors in the brain add a separate appetite effect of their own is still being studied, and the label does not split the appetite effect into a GIP share and a GLP-1 share. What the label and the trial data agree on is the combined result: more weight lost, on average, than single-receptor semaglutide produced in its own trials. Those numbers are next.
Why tirzepatide lasts a week
Native GIP and native GLP-1 share the same weakness. An enzyme called DPP-4 breaks both of them down within minutes of release, which is why your body needs a fresh pulse of each hormone at every meal. A drug built on either hormone has to survive that enzyme to work as anything other than a constant infusion.
Tirzepatide's structure resists DPP-4 breakdown and includes a fatty-acid segment that lets it bind albumin, the most abundant protein in blood. Binding albumin works like a slow-release reservoir. The drug circulates attached to albumin and releases gradually rather than clearing all at once. For the specific titration schedule used in practice, our tirzepatide dosing guide covers each step.
Zepbound and sleep apnea
Zepbound's FDA label also covers a use that has nothing to do with the number on a scale. The label states the drug is approved "to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity," added to the label.
The two trials split on one detail: whether participants were already using positive airway pressure (PAP) therapy, the machine most people associate with sleep apnea treatment.
Tirzepatide reduced the apnea-hypopnea index, or AHI, the standard measure of how many breathing interruptions happen per hour of sleep, in both trials. The same trials also reported drops in body weight, a marker called hypoxic burden, a measure of inflammation called high-sensitivity C-reactive protein, and systolic blood pressure, along with improvement in sleep-related symptoms patients reported themselves.
That combination, fewer breathing interruptions alongside less weight and lower inflammation markers, is the basis for calling Zepbound a sleep apnea treatment rather than only a weight-loss drug that happens to help people who also have OSA.
The SURMOUNT-1 weight-loss numbers
The number most associated with Zepbound comes from SURMOUNT-1, the trial behind the drug's weight-management approval.
Those are the figures that get repeated across comparison charts and news coverage, and they are the reason tirzepatide is often described as the more effective of the two drug classes on a population level, though any individual result varies by dose, adherence, and starting weight.
For a personal estimate at any of the three doses, mapped to your own starting weight, the average Zepbound weight loss calculator uses this same trial data rather than a generic formula. For how tirzepatide's numbers compare directly against semaglutide's, the fuller head-to-head sits at Semaglutide vs Tirzepatide.
What Zepbound does not do
Tirzepatide does not change your metabolism into a new permanent setting, and neither receptor it activates keeps working once the drug clears your system. The appetite and fullness signal is borrowed, the same way semaglutide's is, and it fades when dosing stops. Zepbound is not unusual here. Most chronic-condition medications follow the same pattern once a drug is stopped.
Zepbound's own label is also narrower than people assume. It covers chronic weight management and obstructive sleep apnea. It does not cover type 2 diabetes. That use belongs to Mounjaro, the same tirzepatide molecule sold under a different brand name for a different FDA-approved indication, with its own dosing guidance. Treating the two brands as interchangeable misses that the label, not the molecule, decides what a drug is approved to treat. Our full profile of Zepbound covers price, side effects, and who the FDA cleared it for.
Tirzepatide also does not replace a reduced-calorie diet and physical activity. Both of Zepbound's approved uses name diet and activity as part of the treatment, not an optional add-on, which matches how semaglutide's own label is written for the same reason: the drug makes the deficit easier to sustain, not automatic.
What is tirzepatide's mechanism of action?
Tirzepatide's mechanism of action, in the FDA's own wording, is that it is a GIP receptor and GLP-1 receptor agonist. That means the molecule binds and activates both incretin receptors directly, instead of binding one receptor and relying on a higher dose for a stronger effect. Activating GIP alongside GLP-1 triggers glucose-dependent insulin release from the pancreas, slows gastric emptying, and reaches appetite-regulating regions of the brain, including the hypothalamus. The combination is why researchers classify tirzepatide as a dual incretin agonist rather than grouping it with single-receptor GLP-1 drugs such as semaglutide.
Is Zepbound the same as Mounjaro?
Zepbound and Mounjaro contain the same active drug, tirzepatide, made by the same manufacturer. Each drug carries a different FDA label. Mounjaro's label covers type 2 diabetes. Zepbound's label covers chronic weight management in adults with obesity, or with overweight and a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity. The dosing schedules and approved patient populations differ between the two labels even though the molecule inside the pen is identical.
How is Zepbound different from Ozempic?
Zepbound and Ozempic are different drugs with different mechanisms, each working through its own receptor. Ozempic's active ingredient, semaglutide, activates one receptor, GLP-1. Zepbound's active ingredient, tirzepatide, activates two, GIP and GLP-1. The FDA labels also differ in approved use. Ozempic is approved for type 2 diabetes, while Zepbound is approved for chronic weight management and obstructive sleep apnea.
How fast does Zepbound start working?
Visible weight loss moves on a slower clock. Expecting trial-sized results within a few weeks is a common reason people judge the drug too early.
Does Zepbound treat sleep apnea without weight loss?
No. The SURMOUNT-OSA trials that led to Zepbound's sleep apnea indication measured weight loss alongside the drop in breathing interruptions, and both trials enrolled adults with obesity as a condition of entry, since obesity is a major driver of obstructive sleep apnea. The FDA label approves Zepbound for OSA specifically in adults who also have obesity, not as a stand-alone sleep treatment unrelated to weight. The trials reported that less body weight, along with lower inflammation markers and improved sleep-related symptoms, accompanied the drop in apnea-hypopnea index, consistent with weight loss being part of how the drug improves sleep apnea rather than a separate, unrelated effect.